In February 2007, GW and Otsuka Pharmaceutical announced an exclusive agreement for Otsuka to develop and market Sativex in the United States. Sativex has received permission from the US regulatory authority, the FDA, to enter directly into late stage Phase III trials in the US. The first large scale US trial in the US for cancer patients is expected to start in summer 2007. The 300-patient, double-blind, randomised, placebo-controlled study will evaluate the effect of Sativex in relieving average daily pain, reducing the use of breakthrough opioid medications, improving the quality of sleep and relevant aspects of quality of life among other outcome measures."

from http://en.wikipedia.org/wiki/Sativex .

I wonder if anyone has tried this, perhaps "off label" to manage pain. From my research, it appears that cannabinoids can be effective in the reduction of pain.

US FDA appears to be finally doing their job as for as the approval of this.

"Sativex seems to be a very promising treatment option for patients whose pain does not respond to current analgesics," said Dr. Nathaniel Katz, Assistant Professor of Anesthesia, Tufts University School of Medicine. "The clinical data thus far suggest that many patients who have been suffering with intractable pain may gain significant benefit from the use of Sativex. I welcome GW expanding its research program into the US."